Takeda adds digital health tools in Koneksa deal

The Japanese drugmaker hopes to use biosensor and wearable tech in a number of early-stage clinical trials. 

By Suzanne Elvidge • Nov. 9, 2016

Gilead on the 'hunt for better assets'

One analyst suggests the big biotech, "still on the prowl," might have an eye on Alexion Pharmaceuticals. 

By Judy Packer-Tursman • Nov. 8, 2016

Lexicon buys Bristol neuro drug

The deal stands to further refine Bristol-Myers's pipeline, a trend that has rippled across pharma for much of 2016.

By Jacob Bell • Nov. 8, 2016

Medivir rounds out oncology portfolio with new deal

The Swedish pharma switched gears recently and is bolstering its position in cancer by adding two clinical-stage drugs. 

By Suzanne Elvidge • Nov. 7, 2016

Nestlé invests $145M in food allergy company

Nestlé Health Science's investment could speed development of Aimmune's immunotherapy for peanut allergy.

By Suzanne Elvidge • Nov. 7, 2016

Prescribed Reading: ASH abstracts hit biotech hard

Companies refocus their M&A strategies, while abstracts from the upcoming ASH meeting disappoint investors and new discoveries could help treat a rare disease. 

By Lisa LaMotta • Nov. 4, 2016

EnBiotix gets the bug for AMPT antimicrobials

The bioengineering company has acquired German AMP Therapeutics and its portfolio of anti-microbial peptides. 

By Suzanne Elvidge • Nov. 4, 2016

Troubled Infinity licenses cancer drug to Verastem

The Cambridge-based biotech is attempting to adjust after a terminated partnership with AbbVie and lackluster trial results buried the company's stock. 

By Jacob Bell • Nov. 3, 2016

Ergomed, Asarina partner on treatment for severe premenstrual syndrome

Sepranolone is the first product being developed exclusively for the often-debilitating condition.

By Judy Packer-Tursman • Nov. 3, 2016

Mitsubishi strengthens arthritis portfolio with TissueGene deal

The licensing partnership comes as a growing share of Japan's population is dealing with joint problems.

By Jacob Bell • Nov. 2, 2016

Allergan: More M&A, international expansion

The specialty pharma told analysts during its third quarter call it will continue to focus on deals to flesh out its pipeline. 

By Jacob Bell • Nov. 2, 2016

What would a Salix sale do for Valeant?

The embattled drugmaker confirmed a report from The Wall Street Journal, indicating the Salix portfolio and its top-selling gut drug Xifaxan are on the table. 

By Ned Pagliarulo • Nov. 2, 2016

Astellas furthers oncology focus with Ganymed buy

The deal, which could have Astellas paying upwards of $1.4 billion, gives the company a stronger presence in oncology outside of the blockbuster drug Xtandi.

By Jacob Bell • Oct. 28, 2016

Prescribed Reading: Dealmaking sparse, despite earnings reports

Analysts question Allergan's latest buy, Bristol-Myers shuffles R&D and FDA makes some proclamations about sex. 

By Lisa LaMotta • Oct. 28, 2016

Evotec picks up CRO Cyprotex for $68M

The German drug discovery company has been active in M&A, inking a number of deals over the past several years. 

By Jacob Bell • Oct. 27, 2016

Continuing M&A spree, Allergan picks up Motus for $200M

Allergan has been aggressive in expanding its pipeline, inking a series of stepping-stone deals over the past several months. 

By Ned Pagliarulo • Oct. 27, 2016

Bayer aims to cut costs ahead of Monsanto deal

The German biopharma is trimming its spending as it preps to spend more than $66 billion on Monsanto. 

By Jacob Bell • Oct. 26, 2016

NeuroVive claws back rights to hep B drug

Partner Arbutus Biopharma had halted development of the experimental drug a year ago, but the companies were unable to agree on a path forward until now. 

By Suzanne Elvidge • Oct. 24, 2016

Prescribed Reading: Only one FDA approval in October so far

While few deals flowed in this week, there was plenty of clinical data dominating pharma news.

By Lisa LaMotta • Oct. 21, 2016

AbbVie dumps Ablynx RA drug

Ablynx will have to go it alone in Phase 3 while it looks for a new partner for vobarilizumab. 

By Lisa LaMotta • Oct. 20, 2016

Novartis links up with Cerulean in NDC deal

The Swiss pharma is adding the linker technology to its oncology pipeline as it focuses on combination therapies. 

By Lisa LaMotta • Oct. 19, 2016

Moderna taps Catalent for clinical manufacturing

The well-funded Cambridge biotech has been busy expanding its manufacturing capacity as it ramps up clinical development of several mRNA programs. 

By Jacob Bell • Oct. 17, 2016

PwC: Biotech deal values and volume drop

PwC's latest MoneyTree report depicts a biotech sector struggling to maintain the record levels of investment activity seen last year.

By Suzanne Elvidge • Oct. 17, 2016

Prescribed Reading: AZ sell-off, Merck wins ESMO, generics dominate

Here's a closer look at the clinical trials, M&A, cool science and regulations that are driving the industry this week.

By Lisa LaMotta • Oct. 13, 2016

Intellipharmaceutics and Mallinckrodt ink CNS deal

The companies have signed an agreement to market three central nervous system generics for $3 million in hopes of quick FDA approvals. 

By Joe Cantlupe • Oct. 13, 2016